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Autism spectrum disorders are a set of neurodevelop-mental disorders associated with restrictive or repeti-tive behaviours and difficulties with verbal and inter-
personal communication.1,2 Although the cause of autism 
spectrum disorders is unknown, it appears to be multifacto-
rial, with both environmental factors and a significant 
genetic component playing roles.3,4 The population of the 
Avalon Peninsula in Newfoundland and Labrador has been 
shown to have a unique genetic make-up related to its 
founder population, with higher rates of certain conditions 
with a genetic cause.5–7 Other studies involving this pediatric 
population also found some of the highest global rates of 
type 1 diabetes mellitus,8,9 which has been hypothesized to 
have a possible association with autism.10 We felt it would be 
useful to determine the incidence and prevalence for autism 
spectrum disorder in this part of the world. Our study is one 
of only a few studies that have presented the incidence and 
prevalence data for autism spectrum disorder in any part of 
the Canadian population,11–15 although work is underway to 
create a national autism database.16
The primary aim of our study was to review the incidence 
rate of autism spectrum disorder among children living in the 
Avalon Peninsula at the time of diagnosis over a 5-year period 
(2006–2010). We also used the available data to determine the 
prevalence of autism spectrum disorder for the cohort of chil-
dren born between Jan. 1, 2006, and Dec. 31, 2006, up to Dec. 
31, 2013. Our secondary objectives included examining the 
patient characteristics in children with autism spectrum disorder 
in the Avalon Peninsula, and evaluating some of the diagnostic 
tests performed and the referral patterns among these patients.
Methods
Study population
The study included all children living in the Avalon Peninsula 
between 2006 and 2010. This region is Statistic Canada’s Cen-
sus Division No. 1, Newfoundland and Labrador.17 In addition 
to the unique genetic make-up of this population, the Avalon 
Peninsula was selected because it is a well-defined geographic 
area, which encompasses over 50% of the population of New-
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Background: Recent studies have reported increased prevalence for autism spectrum disorders in a number of geographical loca-
tions. Our objective was to determine the incidence and 1-year cohort prevalence for autism spectrum disorders in children less than 
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John’s), including the identification and specific diagnosis for all children assessed for autism spectrum disorder from 2006 to 2010. 
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dence of new cases increased from 10.1 to 16.7 cases per 10 000 per year from 2006 to 2010. At the end of 2013, the prevalence 
among children born in 2006 was 1 case of autism spectrum disorder per 46 children or 215.77 per 10 000.
Interpretation: We found higher rates of autism spectrum disorder than previously reported for this population. The prevalence in this 
region is also high when compared with other global populations. The high rate of diagnosis supports the need for a provincial autism 
spectrum disorder registry and further research on autism spectrum disorder within this population.
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foundland and Labrador and for whom high-quality clinical 
assessment data were available. The study involved patients 
with a diagnosis of autism spectrum disorder by the Depart-
ment of Child Development at the Janeway Children’s Health 
and Rehabilitation Centre (St. John’s), a part of the Eastern 
Health regional health authority. This department is the only 
child development centre in the region and is the only centre 
giving comprehensive autism spectrum disorder diagnoses to 
patients in this region. Although this department treats chil-
dren from across the province, children were identified as 
being from the Avalon Peninsula if they were living in a com-
munity in Census Division No. 1 at the time of diagnosis. 
Because autism spectrum disorder is almost always diagnosed 
in childhood, we defined the population at risk as children less 
than 15 years of age.
Design
We first calculated the incidence rate by year for a 5-year 
period between 2006 and 2010. We then used the identified 
cases to calculate the prevalence of autism spectrum disorder 
in the cohort born in 2006. Finally, a chart review was con-
ducted on all confirmed cases identified between 2006 and 
2010. A standardized data abstraction form was developed and 
was piloted on 10 charts. The form was then revised, and data 
were abstracted from the remaining charts. The data collected 
included basic demographic information, categorization of the 
type of autism spectrum disorder, comorbidities, type of test-
ing used to diagnose the condition and some of the referral 
patterns for the cases.
Sources of data
This study used data obtained from the Department of Child 
Development at the Janeway Children’s Health and Rehabili-
tation Centre. We included patients with a diagnosis of non-
syndromic autism spectrum disorder confirmed by a multidis-
ciplinary team and who fit the DSM-IV-TR definition of one 
of the autism spectrum disorders, less than 15 years of age, and 
living in the Avalon Peninsula at the time of diagnosis. Diag-
noses were confirmed through multiple observations, consulta-
tion with a developmental pediatrician, a detailed patient his-
tory and, in most instances, the use of at least one module of 
the Autism Diagnostic Observational Schedule.18 Patients who 
did not fit the diagnostic criteria and those with a diagnosis of 
another genetic syndrome that may also have symptoms of 
autism spectrum disorder were excluded. In most instances, 
patients were seen on a continuing basis by the department 
after their diagnosis, which further alleviated concerns about 
misdiagnosis. Patients were first identified from an autism 
spectrum disorder register maintained by the department from 
2005 to 2011. We included all new diagnoses identified from 
Jan. 1, 2006, to Dec. 31, 2010, to allow for the collection of 
data for complete years. This list of patients was then com-
pared with the office records of patients with autism spectrum 
disorder maintained by each developmental pediatrician in the 
department to identify any discrepancies and to ensure no 
patients meeting the inclusion criteria were missed. Although 
not included in the original chart abstraction, we used depart-
ment data to ascertain subsequent patients with a diagnosis of 
autism spectrum disorder who met the 2006 cohort inclusion 
criteria for the period up to Dec. 31, 2013.
Statistical analysis
We calculated incidence by taking the number of new cases 
diagnosed each year and dividing them by the population for 
the region aged less than 15 years (the population at risk). We 
did not have access to data for each specific year for the popu-
lation at risk within the region. We performed a range of sen-
sitivity analyses around the exact population number to use; 
overall, the population was fairly stable over the period so that 
variations in calculating the at-risk population did not have a 
great effect on the reported prevalence or incidence. We used 
a midpoint estimate for the population at risk, calculated by 
averaging the census population aged 0–14  years in 200619 
with that population in 2011,20 resulting in a population of 
39 498. There were no population estimates available that 
included information on age and sex at the level of census 
divisions; therefore, no calculations were made for incidence 
based on these characteristics.
We examined the cohort prevalence for all children born 
in 2006. The numerator was all children in this cohort with a 
diagnosis of autism spectrum disorder by Dec. 31, 2010, and 
the denominator was the average number of children aged 4 
and 5  years reported in the 2011 Canada Census.20. The 
denominator was calculated in this manner because children 
born in 2006 would have been 4 or 5 years of age during data 
collection for the 2011 Canada Census. 20 The population 
data used to calculate incidence and prevalence are reported 
in Appendix 1 (available at www.cmajopen.ca/content/3/3/
E276/suppl/DC1). We updated the prevalence rate in this 
cohort using data until the end of 2013. Confidence intervals 
(95% CIs) were generated for prevalence and incidence based 
on the Poisson error structure. Descriptive analysis and χ2 
analysis were performed on other demographic data using 
Stata Statistical Software, Release 9 (College Station, Texas).
Ethics approval
This study was reviewed and approved by Newfoundland and 
Labrador’s Health Research Ethics Authority.
Results
Between 2006 and 2010, 272 new cases of autism spectrum dis-
order were diagnosed within the study population (Table 1). 
Median age at diagnosis was 3.84 years (interquartile range 
[IQR] 2.76–6.19). Of these 272  patients, 234 were male 
(male:female ratio = 6.2:1). When diagnoses specific to autism 
spectrum disorder were evaluated, 74 (27.2%) patients had 
autistic spectrum disorder, 130 (47.8%) had autistic disorder, 
56 (20.6%) had Asperger syndrome and 12 (4.4%) had perva-
sive developmental disorder-not otherwise specified. Although 
not a specific DSM-IV-TR definition, autism spectrum disor-
der was a common classification given within the department in 
absence of a more specific diagnosis. There was no significant 
variation in specific diagnosis based on year of diagnosis (χ2 test, 
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p = 0.784). At least one module of the Autism Diagnostic 
Observational Schedule18 was completed for 269 of the 
272 patients (98.9%). Module I was used for diagnosis in 112 
(41.6%) patients. Of the 272 patients with a diagnosis, 195 
(71.7%) were referred to the Provincial Intensive Applied 
Behavioural Analysis Program, which is available to children up 
to grade 3; 79 (29.0%) were referred for neuroimaging; and 193 
(71.0%) were referred for genetics follow-up. Our review found 
that many patients had at least one of the comorbidities often 
associated with autism; the most prevalent were behavioural 
issues (n = 28), attention-deficit/hyperactivity disorder (n = 27) 
and anxiety disorder (n = 25). The yearly incidence for 2006 
was 10.1 per 10 000 (95% CI, 7.7–14.4), increasing to 16.7 per 
10 000 (95% CI, 13.3–21.8) by 2010 (Table 2). There was a 
statistically significant difference between the yearly incidence 
in 2006 and in 2010 (p = 0.01).
Cohort prevalence for children born in 2006 was calcu-
lated at the end of 2010, including children between 4 and less 
than 5  years old. Out of an estimated cohort population of 
2668 children based on 2011 Canada Census data, some form 
of autism spectrum disorder was diagnosed in 33 of these chil-
dren, giving an overall prevalence of 123.4  per 10 000 or 1 in 
81 (95% CI, 1 in 56 to 1 in 113). The cohort prevalence for 
children aged 4 years at the end of 2010 was also calculated 
based on sex. The cohort prevalence of autism spectrum dis-
order in males was 1 in 46 (95% CI, 1 in 31 to 1 in 65). The 
cohort prevalence for females was 1 in 431 (95% CI, 1 in 147 
to 1 in 2091). Although not included in the original chart 
abstraction, we obtained data from the Department of Child 
Development to ascertain the number of subsequent patients 
with a diagnosis of autism spectrum disorder who met the 
2006 cohort inclusion criteria. In 2011, 9 additional children 
met the cohort inclusion criteria, 3 patients met the criteria in 
2012 and 13 patients met the criteria in 2013. With the inclu-
sion of these patients, a total of 58 patients had a diagnosis of 
autism spectrum disorder in the 2006 cohort, for an overall 
prevalence of 215.77 per 10 000 or 1 in 46.
Interpretation
We found a high rate of diagnosis of autism spectrum disor-
der in children living in the Avalon Peninsula. The incidence 
of new cases of autism spectrum disorder increased signifi-
Table 1: Characteristics of patients with a diagnosis of ASD, aged 
0–14 yr, living in the Avalon Peninsula, Newfoundland and Labrador
Characteristic
No. of patients (%) 
n = 272
Sex
Male 234 (86.0)
Female 38 (14.0)
Age at diagnosis, yr
  0 < 1 0 (0.0)
  1 < 2 10 (3.7)
  2 < 3 77 (28.3)
  3 < 4 57 (21.0)
  4 < 5 33 (12.1)
  5 < 7 43 (15.8)
  7 < 11 44 (16.2)
11 < 15 8 (2.9)
Specific diagnosis
ASD 74 (27.2)
AD 130 (47.8)
Asperger syndrome 56 (20.6)
PDD-NOS 12 (4.4)
Autism diagnostic observational schedule
Yes 269 (98.9)
No 3 (1.1)
Autism diagnostic observational schedule module (n = 269)
I 112 (41.6)
II 75 (27.9)
III 82 (30.5)
IV 0 (0.0)
Genetics referral
Yes 193 (71.0)
No 1 (0.4)
Unknown 78 (28.6)
Neuroimaging
Yes 79 (29.0)
No 185 (68.0)
Unknown 8 (3.0)
Provincial autism program referral
Yes 195 (71.7)
No 75 (27.6)
Unknown 2 (0.7)
Seizures 14 (5.1)
Birthmarks 14 (5.1)
Congenital anomalies 16 (5.9)
Developmental regression 23 (8.5)
Behavioural issues 28 (10.3)
Dietary restrictions or issues 17 (6.3)
Sleep disturbance 13 (4.8)
GI symptomatology 12 (4.4)
Anxiety 25 (9.2)
OCD 9 (3.3)
Depression 0 (0.0)
ADHD 27 (9.9)
Other 19 (7.0)
Note: AD = autistic disorder, ADHD = attention-deficit/hyperactivity disorder, ASD = 
autism spectrum disorder, GI = gastrointestinal, OCD = obsessive compulsive, 
PDD-NOS = persuasive developmental disorder-not otherwise specified.
Table 2: Number of new ASD diagnoses in patients aged 
0–14 yr in the Avalon Peninsula, Newfoundland and Labrador
Year
No. of cases 
n = 272
Incidence per 10 000 population 
(95% CI)
2006 40 10.1 (7.2–13.7)
2007 50 12.7 (9.4–16.7)
2008 54 13.7 (10.3–17.8)
2009 62 15.7 (12.0–20.1)
2010 66 16.7 (12.9–21.3)
Note: Denominator = 39 498 (average of census populations in 2006 and 2011).
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cantly between 2006 and 2010. By the end of 2013, the cohort 
born in 2006 had one of the highest prevalence rates ever 
reported for a population in Canada. Approximately 70% of 
patients were referred to the provincially funded Intensive 
Applied Behavioural Analysis program or for genetic follow-
up and 29% for neuroimaging exams. There were a range of 
comorbidities also reported in this population, including 
behavioural issues, attention-deficit/hyperactivity disorder and 
anxiety disorder.
Our estimation of prevalence in a particular age cohort is 
similar to the method used by the Autism and Developmental 
Disabilities Monitoring Network in the United States21. This 
US Network used a survey of a cohort of children 8 years of 
age and reported a cohort prevalence ranging from 57 to 
219.14 per 10 000 in 2010. Because of the timeline of our 
study and available data, we used a cohort of children 7 years 
of age at the end of 2013. Our cohort prevalence was 215.77 
per 10 000, which is at the high end of the range of the US 
survey. Similarly, the rates of autism spectrum disorder in the 
Avalon Peninsula are higher compared with other prevalence 
studies. For example, a review of 43 studies of the prevalence 
for autism spectrum disorder that have been published since 
1966 found an average prevalence of 60–70 per 10 000.22 The 
prevalence in our cohort (215.77 per 10 000) was over 3 times 
higher than the median prevalence (62 per 10 000) reported in 
a systematic review in 2012.23 Other studies have found that 
boys are more likely to have an autism spectrum disorder than 
girls, with male-to-female ratios ranging from 2:1 to 6.5:1.24 
We found a male-to-female ratio of 6.2:1, which is at the high 
end of this previously reported range.
Of particular interest is a report with data collected in 
Newfoundland and Labrador that calculated prevalence 
rates for the entire province for some of the same period 
covered by our study.15 They followed a 2-year birth cohort, 
born in 2000–2001, up to 2008. They reported a prevalence 
rate of 61.8/10 000 at 4–5 years of age and 94.2/10 000 at 
6–7 years of age. One reason for the difference between the 
2 studies may be that the other study used cases ascertained 
from “agencies that provide services to children with 
autism.”15 Our study found that only 72.4% of diagnosed 
cases were referred to the provincial program for these ser-
vices. The reasons for this relatively low referral rate are 
unknown, but it may be related to cognitive impairment 
being either too mild or too severe, parental choice, age of 
diagnosis or some other barrier to access. A study involving a 
cohort of children in Nova Scotia reported a similar level of 
agreement (69.1%) between data for autism spectrum disor-
der diagnoses obtained directly from clinical departments 
and data captured from wider administrative sources.25 The 
exact reason for the difference between the data reported by 
Ouellette-Kuntz and colleagues and our data would have to 
be determined by a comparison of the 2  datasets. This 
incongruence points to the difficulty of getting accurate 
prevalence data, particularly when relying on administrative 
datasets, and may support the need to create a registry from 
multiple sources to ensure that all cases of autism spectrum 
disorder in the region are being captured.
Strengths and limitations
This study has a number of strengths. First, it evaluated a 
well-defined geographic area with a fairly stable pediatric 
population. There is only one pediatric development clinic for 
the area to which almost all children suspected of having an 
autism spectrum disorder are referred, which assisted in the 
identification of cases. We identified cases of autism spectrum 
disorder based on detailed patient histories, and observations 
and clinical assessments of a multidisciplinary team that 
included a developmental pediatrician. Most of the cases 
(98.6%) were confirmed using at least one module of the 
Autism Diagnostic Observational Schedule.18 In their review 
of autism spectrum disorder prevalence studies, Elsabbagh 
and colleagues found only 1 other prevalence study that used 
the Autism Diagnostic Observational Schedule, which is con-
sidered the clinical gold standard for diagnosing autism spec-
trum disorder,25 as the primary method of case identifica-
tion.23 For these reasons, our study was able to capture a large 
proportion of children with autism spectrum disorders requir-
ing clinical supervision for a defined population.
Because of the small population studied, changes in the 
number of new cases identified had a substantial impact on 
the prevalence rates. For example, the addition of 25 cases for 
2011–2013 increased the cohort prevalence rate from 123.4 to 
215.77 cases per 10 000. We were limited to the information 
on the patient chart for recording the comorbidities and first-
order family connections, which may have underreported the 
influence of these factors. Although the population appeared 
relatively stable, we were not able to capture specific changes 
in the underlying population, in terms of patient emigration 
and immigrations to the region, which may have impacted the 
calculation of prevalence and incidence. The prevalence and 
incidence rates determined in the study do not reflect possible 
rates in other geographic locations. 
Conclusion
This study adds to the data on the incidence and prevalence of 
autism spectrum disorder in Canada. It also points to the need 
to establish improved methods of tracking autism spectrum dis-
order to ensure that the health burden of the condition is accu-
rately measured. The resources required to enhance opportuni-
ties for children with autism spectrum disorder extend into both 
health and education, which are both provincial responsibilities.
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